Screener
ANI Pharmaceuticals ANIP Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's total equity?
- ANI Pharmaceuticals (ANIP) reported total equity of $597.21M in Q2 2026.
- How has ANI Pharmaceuticals's total equity changed year-over-year?
- ANI Pharmaceuticals's total equity increased by 36.7% year-over-year, from $436.76M to $597.21M.
- What is the long-term trend for ANI Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's total equity has grown at a 22.5% compound annual growth rate (CAGR), from $195.7M to $540.72M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about ANI Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude